Illumina (ILMN) : Traders are bullish on Illumina (ILMN) as it has outperformed the S&P 500 by a wide margin of 2.84% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.37%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.93% in the last 1 week, and is up 0.76% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 1.5% and the 50-Day Moving Average is 6.13%.The 200 Day SMA reached 9.68% Illumina Inc. is up 26.21% in the last 3-month period. Year-to-Date the stock performance stands at -9.89%.
Illumina (ILMN) : The highest short term price target forecast on Illumina (ILMN) is $180 and the lowest target price is $115. A total of 10 equity analysts are currently covering the company. The average price of all the analysts is $152.1 with a standard deviation of $20.63.
Company shares have received an average consensus rating of Hold for the current week Illumina (NASDAQ:ILMN): stock was range-bound between the intraday low of $171.77 and the intraday high of $175.05 after having opened at $175.05 on Fridays session. The stock finally closed in the red at $175.05, a loss of -1.13%. The stock remained in the red for the whole trading day. The total traded volume was 1,525,409 shares. The stock failed to cross $175.05 in Fridays trading. The stocks closing price on Thursday was $174.94.
Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.